Virpax Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Virpax Pharmaceuticals'in kazançlarının artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 48.7% oranında azalması beklenmektedir.

Anahtar bilgiler

1.9%

Kazanç büyüme oranı

48.7%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.8%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	09 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:VRPX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-9	N/A	N/A	1
12/31/2025	N/A	-8	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	1
9/30/2024	N/A	-13	-17	-17	N/A
6/30/2024	N/A	-17	-15	-15	N/A
3/31/2024	N/A	-17	-16	-16	N/A
12/31/2023	N/A	-15	-10	-10	N/A
9/30/2023	N/A	-14	-8	-8	N/A
6/30/2023	N/A	-15	-11	-11	N/A
3/31/2023	N/A	-18	-14	-14	N/A
12/31/2022	N/A	-22	-18	-18	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-18	-20	-20	N/A
3/31/2022	N/A	-15	-18	-18	N/A
12/31/2021	N/A	-12	-15	-15	N/A
9/30/2021	N/A	-9	-10	-10	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-6	-4	-4	N/A
12/31/2020	N/A	-4	-1	-1	N/A
9/30/2020	N/A	-4	-2	-2	N/A
6/30/2020	N/A	-4	-1	-1	N/A
3/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	-3	-1	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: VRPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: VRPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: VRPX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: VRPX şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: VRPX gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: VRPX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Virpax Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Recent updates

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million.

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

High number of new and inexperienced directors

Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price

New major risk - Revenue and earnings growth

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Shareholder dilution

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million.

Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1)

New major risk - Financial position

Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2)

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing

Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review

Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Novvae Pharmaceuticals Announces Executive Appointments

Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals

Virpax Pharmaceuticals, Inc. Announces Update on Litigation

Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method

New major risk - Market cap size

Virpax Pharmaceuticals, Inc. Announces CFO Changes

New minor risk - Share price stability

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023

Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director

Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology

Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar

Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022

Chairman & CEO recently bought US$102k worth of stock

Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324

Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm

Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee

Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Chairman & CEO recently bought US$100k worth of stock

Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd.

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million.

Virpax: Targeting Pain At Its Source

Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta

Virpax Pharmaceuticals shares surge on Envelta IND update

Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm)

Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin